This inventor holds 3 USPTO granted patents and 4 published patent applications and 1 EPO patent. Top assignee: Yale University. Active years: 2015-2020.
Company Filing History:
Years Active: 2015-2020
Title: Wajahat Mehal: Innovator in Liver Disease Treatment and Biomaterial Response
Introduction
Wajahat Mehal is a prominent inventor based in Guilford, CT (US). He has made significant contributions to the field of medical science, particularly in the treatment of liver diseases and the regulation of host responses to biomaterials. With a total of 3 patents, his work is paving the way for innovative therapeutic methods.
Latest Patents
One of Wajahat Mehal's latest patents focuses on compositions and methods useful for treating or preventing liver diseases or disorders, as well as promoting weight loss. This invention includes a method for preventing or treating toxic liver diseases, such as non-alcoholic steatohepatitis (NASH) and alcoholic hepatitis, among others. The method involves administering a therapeutically effective dose of at least one cardiac glycoside or its derivatives to the subject.
Another significant patent relates to compositions and methods for inhibiting inflammation from and rejection of biomaterials. This invention utilizes salicylate compounds and TLR7/TLR9 antagonists to regulate the host response to biomaterials, thereby enhancing their acceptance in medical applications.
Career Highlights
Wajahat Mehal is affiliated with Yale University, where he conducts research and develops innovative solutions in the medical field. His work has garnered attention for its potential to improve patient outcomes in liver disease management and biomaterial integration.
Collaborations
Wajahat has collaborated with notable colleagues, including Themis Kyriakides and Avlin Imaeda, to advance research in his areas of expertise. Their combined efforts contribute to the development of effective treatments and methodologies.
Conclusion
Wajahat Mehal's contributions to medical science through his patents and research at Yale University highlight his commitment to innovation in healthcare. His work not only addresses critical health issues but also sets the stage for future advancements in the treatment of liver diseases and biomaterial responses.